Givinostat

Drug Profile

Givinostat

Alternative Names: Histone deacetylase inhibitors - Italfarmaco; ITF-2357

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Italfarmaco
  • Developer Italfarmaco; Radboud University
  • Class Amines; Antineoplastics; Carbamates; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Histone demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Juvenile rheumatoid arthritis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myeloproliferative disorders
  • Phase I/II Duchenne muscular dystrophy; Polycythaemia vera
  • No development reported Hereditary autoinflammatory diseases; Juvenile rheumatoid arthritis
  • Discontinued Diffuse large B cell lymphoma; Hodgkin's disease; Multiple myeloma

Most Recent Events

  • 13 Feb 2017 No development reported - Phase-II for Hereditary autoinflammatory diseases in Netherlands (PO) (NCT00442182)
  • 28 Jul 2016 Italfarmaco plans a phase III trial in Duchenne muscular dystrophy (In children, In adolescents) in USA (NCT02851797)
  • 14 Sep 2015 Givinostat is still in phase II trials for Myeloproliferative disorders in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top